The association of cytochrome 7A1 and ATP-binding cassette G8 genotypes with type 2 diabetes among Jordanian patients.
ATP Binding Cassette Transporter, Subfamily G, Member 8
/ genetics
ATP-Binding Cassette Transporters
/ genetics
Adenosine Triphosphate
Cholesterol
/ metabolism
Cholesterol 7-alpha-Hydroxylase
/ genetics
Cytochromes
/ genetics
Diabetes Mellitus, Type 2
/ genetics
Genotype
Humans
Jordan
Polymorphism, Single Nucleotide
ABCG8
CYP7A1
Jordan
diabetes mellitus
genetic variants
Journal
Drug metabolism and personalized therapy
ISSN: 2363-8915
Titre abrégé: Drug Metab Pers Ther
Pays: Germany
ID NLM: 101653409
Informations de publication
Date de publication:
29 11 2021
29 11 2021
Historique:
received:
14
07
2021
accepted:
20
09
2021
pubmed:
1
12
2021
medline:
28
6
2022
entrez:
30
11
2021
Statut:
epublish
Résumé
Increased cholesterol levels were found to be associated with diabetes mellitus type II (DM2). The cholesterol is metabolized by cytochrome 7A1 (CYP7A1) and transported in the intestine by ATP-binding cassette G8 (ABCG8). Genetic variants in A total of 117 DM2 patients and 100 healthy controls, of Jordanian Arabic origin, were genotyped for The study showed that homozygosity of The results of this study indicate that
Identifiants
pubmed: 34845882
pii: dmdi-2021-0164
doi: 10.1515/dmpt-2021-0164
doi:
Substances chimiques
ABCG8 protein, human
0
ATP Binding Cassette Transporter, Subfamily G, Member 8
0
ATP-Binding Cassette Transporters
0
Cytochromes
0
Adenosine Triphosphate
8L70Q75FXE
Cholesterol
97C5T2UQ7J
CYP7A1 protein, human
EC 1.14.14.23
Cholesterol 7-alpha-Hydroxylase
EC 1.14.14.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-154Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Bardini, G, Rotella, CM, Giannini, S. Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications. Rev Diabet Stud 2012;9:82–93. https://doi.org/10.1900/rds.2012.9.82.
Taylor, R. Type 2 diabetes: etiology and reversibility. Diabetes Care 2013;36:1047–55. https://doi.org/10.2337/dc12-1805.
Kannel, WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110:1100–7. https://doi.org/10.1016/0002-8703(85)90224-8.
Cholesterol Treatment Trialists, C, Kearney, PM, Blackwell, L, Collins, R, Keech, A, Simes, J, et al.. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117–25. https://doi.org/10.1016/S0140-6736(08)60104-X.
Mooradian, AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metabol 2009;5:150–9. https://doi.org/10.1038/ncpendmet1066.
Schofield, JD, Liu, Y, Rao-Balakrishna, P, Malik, RA, Soran, H. Diabetes dyslipidemia. Diabetes Ther 2016;7:203–19. https://doi.org/10.1007/s13300-016-0167-x.
Jiang, XY, Zhang, Q, Chen, P, Li, SY, Zhang, NN, Chen, XD, et al.. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J Clin Pharm Therapeut 2012;37:719–23. https://doi.org/10.1111/j.1365-2710.2012.01372.x.
Wei, KK, Zhang, LR, Zhang, Y, Hu, XJ. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin. J Clin Pharm Therapeut 2011;36:725–33. https://doi.org/10.1111/j.1365-2710.2010.01227.x.
Hubacek, JA, Berge, KE, Stefkova, J, Pitha, J, Skodova, Z, Lanska, V, et al.. Polymorphisms in ABCG5 and ABCG8 transporters and plasma cholesterol levels. Physiol Res 2004;53:395–401.
Kajinami, K, Brousseau, ME, Nartsupha, C, Ordovas, JM, Schaefer, EJ. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res 2004;45:653–6. https://doi.org/10.1194/jlr.m300278-jlr200.
Abed, E, Jarrar, Y, Alhawari, H, Abdullah, S, Zihlif, M. How the cytochrome 7A1 (CYP7A1) and ATP-binding cassette G8 (ABCG8) genetic variants affect atorvastatin response among type 2 diabetic patients attending the University of Jordan Hospital. Int J Clin Pharmacol Therapeut 2021;59:99–108. https://doi.org/10.5414/cp203779.
Umpierre, D, Ribeiro, PA, Kramer, CK, Leitao, CB, Zucatti, AT, Azevedo, MJ, et al.. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. J Am Med Assoc 2011;305:1790–9. https://doi.org/10.1001/jama.2011.576.
Bochkov, VN, Oskolkova, OV, Birukov, KG, Levonen, AL, Binder, CJ, Stockl, J. Generation and biological activities of oxidized phospholipids. Antioxidants Redox Signal 2010;12:1009–59. https://doi.org/10.1089/ars.2009.2597.
Srivastava, A, Choudhuri, G, Mittal, B. CYP7A1 (-204 A>C; rs3808607 and -469 T>C; rs3824260) promoter polymorphisms and risk of gall bladder cancer in North Indian population. Metabolism 2010;59:767–73. https://doi.org/10.1016/j.metabol.2009.09.021.
Qrafli, M, Amar, Y, Bourkadi, J, Ben Amor, J, Iraki, G, Bakri, Y, et al.. The CYP7A1 gene rs3808607 variant is associated with susceptibility of tuberculosis in Moroccan population. Pan Afr Med J 2014;18:1. https://doi.org/10.11604/pamj.2014.18.1.3397.
Fu, L, Zhao, Y, Wu, X, Liu, H, Shi, J, Lu, J, et al.. CYP7A1 genotypes and haplotypes associated with hypertension in an obese Han Chinese population. Hypertens Res 2011;34:722–7. https://doi.org/10.1038/hr.2011.18.
Zhao, GX, Liu, Y, Li, ZX, Lv, CZ, Traboulsee, A, Sadovnick, AD, et al.. Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population. Neurosci Bull 2013;29:525–30. https://doi.org/10.1007/s12264-013-1347-6.
Al-sheikh, NM, El-Hefnway, SM, El-Shetahy, AA. Cholesterol 7-alpha hydroxylase gene (CYP7A1) promoter polymorphism rs3808607 as a risk factor for pulmonary tuberculosis in Egypt. Meta Gene 2018;16:66–71. https://doi.org/10.1016/j.mgene.2018.01.012.
Renner, O, Lutjohann, D, Richter, D, Strohmeyer, A, Schimmel, S, Muller, O, et al.. Role of the ABCG8 19H risk allele in cholesterol absorption and gallstone disease. BMC Gastroenterol 2013;13:30. https://doi.org/10.1186/1471-230x-13-30.
Koeijvoets, KC, van der Net, JB, Dallinga-Thie, GM, Steyerberg, EW, Mensink, RP, Kastelein, JJ, et al.. ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia. Atherosclerosis 2009;204:453–8. https://doi.org/10.1016/j.atherosclerosis.2008.09.018.
Hubacek, JA, Pitha, J, Skodova, Z, Poledne, R, Lanska, V, Waterworth, DM, et al.. Polymorphisms in CYP-7A1, not APOE, influence the change in plasma lipids in response to population dietary change in an 8 year follow-up; results from the Czech MONICA study. Clin Biochem 2003;36:263–7. https://doi.org/10.1016/s0009-9120(03)00025-0.
Milanizadeh, S, Mohebbi, SR, Khanyaghma, M, Mohammad Alizadeh, AH. ATP binding cassette and cholecystokinin A receptor genetic variations in gallstone susceptibility. Gastroenterol Hepatol Bed Bench 2017;10:S108–16.
Grunhage, F, Acalovschi, M, Tirziu, S, Walier, M, Wienker, TF, Ciocan, A, et al.. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 2007;46:793–801. https://doi.org/10.1002/hep.21847.
Li, Q, Wei, XL, Yin, RX. Association of ATP binding cassette transporter G8 rs4148217 SNP and serum lipid levels in Mulao and Han nationalities. Lipids Health Dis 2012;11:46. https://doi.org/10.1186/1476-511x-11-46.
Plat, J, Bragt, MC, Mensink, RP. Common sequence variations in ABCG8 are related to plant sterol metabolism in healthy volunteers. J Lipid Res 2005;46:68–75. https://doi.org/10.1194/jlr.m400210-jlr200.
Bertoluci, MC, Rocha, VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndrome 2017;9:25. https://doi.org/10.1186/s13098-017-0225-1.
Alhawari, H, Jarrar, Y, AlKhatib, MA, Alhawari, H, Momani, M, Zayed, A, et al.. The association of 3-hydroxy-3-methylglutaryl-CoA reductase, apolipoprotein E, and solute carrier organic anion genetic variants with atorvastatin response among Jordanian patients with type 2 diabetes. Life (Basel) 2020;10:232. https://doi.org/10.3390/life10100232.
Cavaiola, TS, Pettus, JH. Management of type 2 diabetes: selecting amongst available pharmacological agents. In: Feingold, KR, Anawalt, B, Boyce, A, Chrousos, G, de Herder, WW, Dhatariya, K, editors, et al.. South Dartmouth (MA): Endotext; 2000.
Elnaem, MH, Mohamed, MHN, Huri, HZ, Azarisman, SM, Elkalmi, RM. Statin therapy prescribing for patients with type 2 diabetes mellitus: a review of current evidence and challenges. J Pharm BioAllied Sci 2017;9:80–7. https://doi.org/10.4103/jpbs.JPBS_30_17.
Kim, SK, Yim, SV, Lee, BC. Association between cytochrome P450 promoter polymorphisms and ischemic stroke. Exp Ther Med 2012;3:261–8. https://doi.org/10.3892/etm.2011.388.
Jarrar, YB, Balasmeh, AA, Jarrar, W. Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers. Libyan J Med 2018;13:1408381. https://doi.org/10.1080/19932820.2017.1408381.
Hakooz, N, Jarrar, YB, Zihlif, M, Imraish, A, Hamed, S, Arafat, T. Effects of the genetic variants of organic cation transporters 1 and 3 on the pharmacokinetics of metformin in Jordanians. Drug Metab Pers Ther 2017;32:157–62. https://doi.org/10.1515/dmpt-2017-0019.
Matthan, NR, Pencina, M, LaRocque, JM, Jacques, PF, D’Agostino, RB, Schaefer, EJ, et al.. Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res 2009;50:1927–35. https://doi.org/10.1194/jlr.p900039-jlr200.
Nicolas, A, Fatima, S, Lamri, A, Bellili-Munoz, N, Halimi, JM, Saulnier, PJ, et al.. ABCG8 polymorphisms and renal disease in type 2 diabetic patients. Metabolism 2015;64:713–9. https://doi.org/10.1016/j.metabol.2015.03.005.
Srivastava, A, Garg, N, Srivastava, A, Srivastava, K, Mittal, B. Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy. Dis Markers 2010;28:307–13. https://doi.org/10.1155/2010/357304.